Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 43 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Moderna mRNA-1273 vaccine Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine

NCT04811664
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Moderna COVID-19 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 29 Years
Enrollment
1,923 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
51
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

COVID-19 Protection After Transplant Pilot Study

NCT04969263
View directory record Official record
Conditions
Kidney Transplant Recipients
Interventions
BNT162b2 vaccine (Pfizer/BioNTech), mRNA-1273 vaccine (Moderna)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

NCT04813796
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1283, mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
5
States / cities
Chandler, Arizona • San Diego, California • Melbourne, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

NCT05119855
View directory record Official record
Conditions
Papillomavirus Infections, Coronavirus Disease (COVID-19)
Interventions
9vHPV Vaccine, mRNA-1273 Vaccine
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
9 Years to 11 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
38
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants

NCT04927065
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273.211, mRNA-1273, mRNA-1273.617.2, mRNA-1273.213, mRNA-1273.529, mRNA-1273.214, mRNA-1273.222, mRNA-1273.815, mRNA-1273.231
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5,161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
23
States / cities
Sacramento, California • Hollywood, Florida • Jacksonville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 6, 2026, 1:03 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

COVID-19 Vaccine Responses in PIDD Subjects

NCT05321407
View directory record Official record
Conditions
X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency, CVID, Common Variable Immunodeficiency, Primary Antibody Deficiencies, Secondary Hypogammaglobulinemia
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
6 Months and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
3
States / cities
St. Petersburg, Florida • Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

NCT04889209
View directory record Official record
Conditions
COVID-19
Interventions
Ad26.COV2.S, BNT162b2, mRNA-1273, mRNA-1273.211, mRNA-1273.222, SARS-CoV-2 rS/M1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
867 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
10
States / cities
Decatur, Georgia • Baltimore, Maryland • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19

NCT05815498
View directory record Official record
Conditions
COVID-19
Interventions
mRNA-1283.222, mRNA-1273.222, mRNA-1283.815, mRNA-1273.815
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Years and older
Enrollment
13,553 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
161
States / cities
Huntsville, Alabama • Vestavia Hills, Alabama • Chandler, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 6, 2026, 1:03 PM EDT
Completed No phase listed Observational

COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose

NCT05392075
View directory record Official record
Conditions
COVID-19 Pneumonia, COVID-19
Interventions
Pfizer COVID-19 mRNA vaccine, Moderna COVID-19 mRNA vaccine
Biological
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 6, 2026, 1:03 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Impact of COVID-19 on Maternal and Neonatal Outcomes

NCT05197621
View directory record Official record
Conditions
COVID-19, Pregnancy; Infection
Interventions
mRNA COVID-19 vaccine (Pfizer or Moderna)
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
14 Years to 55 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers

NCT04852978
View directory record Official record
Conditions
Healthy, Chronic Stable Illness
Interventions
casirivimab+imdevimab, Moderna mRNA-1273 vaccine
Drug · Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
6
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Hialeah, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 6, 2026, 1:03 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)

NCT04930055
View directory record Official record
Conditions
Cancer
Interventions
COVID-19 Vaccination
Biological
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
2,206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

NCT04969276
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Quadrivalent Inactivated Influenza High Dose, COVID-19 mRNA Vaccine (nucleoside modified)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
306 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
6
States / cities
Glendale, Arizona • San Diego, California • Vista, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 6, 2026, 1:03 PM EDT
Recruiting No phase listed Observational

COVID-19 Vaccines Safety Tracking (CoVaST)

NCT04834869
View directory record Official record
Conditions
Adverse Reaction to Vaccine, COVID19 Vaccine
Interventions
BNT162b2, mRNA-1273, AZD1222, CoronaVac, Sinopharm, Gam-COVID-Vac, JNJ-78436735, CVnCoV, NVX-CoV2373, BBV152
Biological
Lead sponsor
Masaryk University
Other
Eligibility
18 Years and older
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

NCT04649151
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, Placebo, mRNA-1273.222
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Years to 18 Years
Enrollment
4,328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
48
States / cities
Banning, California • La Mesa, California • Lake Worth, Florida + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 6, 2026, 1:03 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS

NCT05279365
View directory record Official record
Conditions
SARS CoV 2 Infection, COVID-19
Interventions
Pfizer/BioNTech (BNT162b2), Moderna
Biological
Lead sponsor
DHR Health Institute for Research and Development
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Brownsville, Texas • Edinburg, Texas • Rio Grande City, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 6, 2026, 1:03 PM EDT
Active, not recruiting No phase listed Observational

A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)

NCT06189053
View directory record Official record
Conditions
Myocarditis
Interventions
Not listed
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 6, 2026, 1:03 PM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT05000216
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 6, 2026, 1:03 PM EDT
Completed No phase listed Observational

COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients

NCT05054218
View directory record Official record
Conditions
Covid19, SARS-CoV2 Infection
Interventions
mRNA-1273
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 6, 2026, 1:03 PM EDT